[Clinical and prognostic usefulness of Ki67 determination in breast carcinoma].
We studied the correlation between tumor size, nodal status, menopausal status, nuclear oestrogen receptors, disease free survival and Ki67 (proliferation rate) measured by mean of immunohistochemical analysis with monoclonal antibody. Median value was 10%. From December 1986 to October 1989 we studied 236 consecutive patients (pts). Median follow up was 34 months (range 7-51 months). Median age was 56 years (r. 26-82). We observed: 1) lower levels in smaller tumors; 2) poor correlation with nodes involvement; 3) lower levels when nuclear oestrogen receptors were positive. Preliminary data seem to suggest longer disease free survival when Ki67 is low.
Gottardi
O
O
Divisione di Oncologia Medica Falck, Ospedale Niguarda Cà Granda, Milano.
Tabiadon
D
D
Scanzi
F
F
Bono
A
A
Majno
M
M
Ferrari
M
M
Colombo
P
P
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry*; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000276:immunology*; D009687:Nuclear Proteins / Q000276:immunology*; D011379:Prognosis
D000911:Antibodies, Monoclonal; D019394:Ki-67 Antigen; D009363:Neoplasm Proteins; D009687:Nuclear Proteins
Utilità clinica e prognostica della determinazione del ki67 nel carcinoma mammario.